Pharmaceutical Era

Search your requirement

  • Home
  • Press Releases
    • Submit Release
  • Events
  • Reach Us

Social media

Pharmaceutical Era Pharmaceutical Era
  • Home
  • Press Releases
    • Submit Release
  • Events
  • Reach Us
MilliporeSigma receives the industry
MilliporeSigma receives the industry's first EXCiPACT certification for cell culture media manufacturing
Ibex Medical Analytics achieves notable milestones with its AI-first approach to cancer diagnostics
Ibex Medical Analytics achieves notable milestones with its AI-first approach to cancer diagnostics
Albertsons Companies pharmacies now offer COVID and flu vaccines to help protect communities this respiratory virus season
Albertsons Companies pharmacies now offer COVID and flu vaccines to help protect communities this respiratory virus season
OmniSYS rebrands as XiFin Pharmacy Solutions, launches Pharmacy Payor Rate Transparency Monitor, and earns the Pharmacy 500 Award
OmniSYS rebrands as XiFin Pharmacy Solutions, launches Pharmacy Payor Rate Transparency Monitor, and earns the Pharmacy 500 Award
Gilead’s Livdelzi (Seladelpar) receives FDA accelerated approval for primary biliary cholangitis
Gilead’s Livdelzi (Seladelpar) receives FDA accelerated approval for primary biliary cholangitis
ProJenX announces the formation of its Clinical Advisory Board
ProJenX announces the formation of its Clinical Advisory Board
Citius Pharmaceuticals
Citius Pharmaceuticals' LYMPHIR™ wins FDA approval for relapsed/refractory cutaneous T-cell lymphoma
NewAmsterdam Pharma announces positive topline data from the Phase 3 BROOKLYN trial of Obicetrapib in heterozygous familial hypercholesterolemia patients
NewAmsterdam Pharma announces positive topline data from the Phase 3 BROOKLYN trial of Obicetrapib in heterozygous familial hypercholesterolemia patients
Cygnus Technologies and TriLink BioTechnologies® collaborate to launch AccuRes™ Host Cell DNA Quantification Kits
Cygnus Technologies and TriLink BioTechnologies® collaborate to launch AccuRes™ Host Cell DNA Quantification Kits
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules.
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules.
Updated flu and COVID-19 vaccinations are now available at CVS Pharmacy® and MinuteClinic
Updated flu and COVID-19 vaccinations are now available at CVS Pharmacy® and MinuteClinic
FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma
FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma

Featured Press Releases

MalarVx licenses HDT Bio

MalarVx licenses HDT Bio's repRNA/LION™ technology to develop a groundbreaking malaria vaccine

Biotheryx Announces First Patient Dosed in Phase 1 Clinical Trial of BTX-9341

Biotheryx Announces First Patient Dosed in Phase 1 Clinical Trial of BTX-9341

  • 17 Jul 2024

Biotheryx, Inc., a biopharmaceutical company discovering and developing a portfolio of...

A convenient and cost-effective way to treat sickle cell disease may be offered by Vascarta

A convenient and cost-effective way to treat sickle cell disease may be offered by Vascarta's patented transdermal drug candidate

UroMems Appoints Former Axonics Executive Rinda Sama to Board of Directors

UroMems Appoints Former Axonics Executive Rinda Sama to Board of Directors

AIM ImmunoTech announces the release of the next CEO Corner segment

AIM ImmunoTech announces the release of the next CEO Corner segment

Prestigious Journal of Hematology & Oncology Accepts HanchorBio’s Novel CD47-SIRPα Therapeutic, HCB101, for Publication

Prestigious Journal of Hematology & Oncology Accepts HanchorBio’s Novel CD47-SIRPα Therapeutic, HCB101, for Publication

Eli Lilly’s Foundayo™: The Newest GLP-1 Innovation Offered by Ro

Eli Lilly’s Foundayo™: The Newest GLP-1 Innovation Offered by Ro

  • By Ro
  • Ro
  • 09 Apr 2026
Approval and Launch of Nintedanib Capsules

Approval and Launch of Nintedanib Capsules

  • By Dexcel Pharma USA
  • Dexcel Pharma USA
  • 09 Apr 2026
When Every Beat Matters, BD Helps Clinicians Gain Continuous, Noninvasive Blood Pressure Insight to Eliminate Blind Spots

When Every Beat Matters, BD Helps Clinicians Gain Continuous, Noninvasive Blood Pressure Insight to Eliminate Blind Spots

  • By BD
  • BD
  • 07 Apr 2026
Dr. Amit Singal Appointed as Chief Medical Officer by Curve Biosciences

Dr. Amit Singal Appointed as Chief Medical Officer by Curve Biosciences

  • By Curve Biosciences
  • Curve Biosciences
  • 07 Apr 2026
MEDIPEEL Gains Momentum in the K-Pharmacy Channel in Korea.

MEDIPEEL Gains Momentum in the K-Pharmacy Channel in Korea.

  • By MEDIPEEL
  • MEDIPEEL
  • 06 Apr 2026
Epia Neuro Launches Intent-Driven Neural Technology to Restore Function After Stroke and Address Cognitive Decline

Epia Neuro Launches Intent-Driven Neural Technology to Restore Function After Stroke and Address Cognitive Decline

  • By Epia Neuro
  • Epia Neuro
  • 06 Apr 2026
Log in
Show
  • Create an account
  • Forgot your username?
  • Forgot your password?
Drug Discovery 2024
The Digital Pharma Advances Conference 2026

Most Popular

  • ENFLONSIA™ (clesrovimab) shows positive new results in infants and children under 2 at increased risk of severe RSV disease across two seasons, Merck reports
    ENFLONSIA™ (clesrovimab) shows positive new results in infants and children under 2 at increased risk of severe RSV disease across two seasons, Merck reports
    By Merck & Co., Inc.
    Feb 19
  • AdvanCell Proudly Announces $18M in MRFF Frontiers Initiative Funding to Advance Targeted Alpha Therapy for Defeating Prostate Cancer
    AdvanCell Proudly Announces $18M in MRFF Frontiers Initiative Funding to Advance Targeted Alpha Therapy for Defeating Prostate Cancer
    By AdvanCell
    Apr 14
  • Aptar’s Nasal Unidose System will deliver neffy® (epinephrine nasal spray), the first FDA-approved needle-free treatment for Type I allergic reactions, including anaphylaxis
    Aptar’s Nasal Unidose System will deliver neffy® (epinephrine nasal spray), the first FDA-approved needle-free treatment for Type I allergic reactions, including anaphylaxis
    By AptarGroup, Inc.
    Aug 15
April   2026
M T W T F S S
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30      

User Area

  • Login page
  • Registration
  • Edit Profile
  • Forgot Password

Discover

  • About Us
  • Terms Of Use
  • Privacy Policy
  • FAQs

Engage with Us

  • Search on Site
  • Post Press Release
  • Promote Brand
  • List Your Event

Subscribe for e-Newsletter Monthly

Subscribe to the Pharmaceutical Era newsletter to receive timely updates from your favorite products.
loader
Antispam refresh
© Pharmaceutical Era — A product of HISSM. All Rights Reserved.
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. To find out more, please click here.